Skip to main content Accessibility help
×
Hostname: page-component-cd9895bd7-dk4vv Total loading time: 0 Render date: 2024-12-28T01:48:41.934Z Has data issue: false hasContentIssue false

Chapter 7 - Cervical Cancer Screening

Published online by Cambridge University Press:  23 October 2024

Laurie J. Mckenzie
Affiliation:
University of Texas MD Anderson Cancer Center, Houston
Denise R. Nebgen
Affiliation:
University of Texas MD Anderson Cancer Center, Houston
Get access

Summary

Though both preventable and curable, cervical cancer remains a leading cause of cancer-related deaths globally. It is generally understood that the overwhelming majority of cervical cancer cases are caused by persistent infection with high-risk human papillomavirus infection. In addition to other well-studied risk factors, it is well-established in the literature that there is an increased risk of progression from preinvasive disease to invasive cancer in women with immunosuppression, such as those living with human immunodeficiency virus (HIV) and those with cancer. In this chapter, we seek to summarize recommendations surrounding cervical cancer screening and treatment for women with who are immunosuppressed following cancer therapy. We review the use of cervical cytology and HPV testing and discuss their use in both patients of average and increased risk. We also review the American Society of Colposcopy and Cervical Pathology (ASCCP) guidelines for treatment of preinvasive disease in immunocompromised patients.

Type
Chapter
Information
Caring for the Female Cancer Patient
Gynecologic Considerations
, pp. 107 - 116
Publisher: Cambridge University Press
Print publication year: 2024

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

World Health Organization. Cervical Cancer Elimination Initiative. www.who.int/initiatives/cervical-cancer-elimination-initiative#cms. Accessed 8 March 8, 2022.Google Scholar
Arbyn, M., Weiderpass, E., Bruni, L., et al. Estimates of incidence and mortality of cervical cancer in 2018: A worldwide analysis. Lancet Glob Heal. 2020;8:e191e203.CrossRefGoogle ScholarPubMed
Bray, F., Ferlay, J., Soerjomataram, I., et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancer in 185 countries. CA Cancer J Clin. 2018;68:394424.CrossRefGoogle ScholarPubMed
Bansal, N., Wright, J. D., Cohen, C. J., Herzog, T. J. Natural history of established low grade cervical intraepithelial (CIN 1) lesions. Anticancer Res. 2008;28:1763–6.Google ScholarPubMed
Castle, P. E., Schiffman, M., Wheeler, C. M., Solomon, D. Evidence for frequent regression of cervical intraepithelial neoplasia-grade 2. Obstet Gynecol. 2009;113:1825.CrossRefGoogle ScholarPubMed
Ostör, A. Natural history of cervical intraepithelial neoplasia: A critical review. Int J Gynecol Pathol. 1993;12:186–92.CrossRefGoogle ScholarPubMed
Walboomers, J., Jacobs, M., Manos, M., et al. Human papillomavirus is a necessary cause. J Pathol. 1999;189:1219.3.0.CO;2-F>CrossRefGoogle ScholarPubMed
Wolf, J. K., Ramirez, P. T. The molecular biology of cervical cancer. Cancer Invest. 2001;19:621–9.CrossRefGoogle ScholarPubMed
Bosch, X., Harper, D. Prevention strategies of cervical cancer in the HPV vaccine era. Gynecol Oncol. 2006;103:21–4.CrossRefGoogle ScholarPubMed
Chesson, H., Dunne, E., Hariri, S., Markowitz, L. The estimated lifetime probability of acquiring human papillomavirus in the United States. Sex Transm Dis. 2014; 41:660–4.CrossRefGoogle ScholarPubMed
Moscicki, A.-B. Management of adolescents with abnormal cytology and histology for OBGYN Clinics of North America. Obs Gynecol Clin North Am. 2008;35:633–43.Google Scholar
Schiffman, M., Doorbar, J., Wentzensen, N., et al. Carcinogenic human papillomavirus infection. Nat Rev Dis Prim. 2016; https://doi.org/10.1038/nrdp.2016.86.CrossRefGoogle Scholar
Lee, Y. C. A., Hashibe, M. Tobacco, alcohol, and cancer in low and high income countries. Ann Glob Heal. 2014;80:378–83.Google ScholarPubMed
Berrington De, González, A., Green, J. Comparison of risk factors for invasive squamous cell carcinoma and adenocarcinoma of the cervix: Collaborative reanalysis of individual data on 8,097 women with squamous cell carcinoma and 1,374 women with adenocarcinoma from 12 epidemiological studies. Int J Cancer. 2007;120:885–91.Google Scholar
Ferenczy, A., Coutlee, F., Franco, E., Hankins, C. Human papillomavirus and HIV coinfection and the risk of neoplasias of the lower genital tract: A review of recent developments. Can Med Assoc J. 2003;169:431–4.Google ScholarPubMed
Wang, Y., Brinch, L., Jebsen, P., Tanbo, T., Kirschner, R. A clinical study of cervical dysplasia in long-term survivors of allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2012;18:747–53.CrossRefGoogle ScholarPubMed
The Future II Study Group. Quadrivalent vaccine against human pappilomavirus to prevent high-grade cervical lesions. N Engl J Med. 2006;355:1120.Google Scholar
Paavonen, J., Naud, P., Salmerón, J., et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): Final analysis of a double-blind, randomised study in young women. Lancet. 2009;374:301–14.CrossRefGoogle ScholarPubMed
Joura, E. A., Giuliano, A. R., Iversen, O.-E., et al. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med. 2015;372:711–23.CrossRefGoogle ScholarPubMed
Lei, J., Ploner, A., Elfström, K. M., et al. HPV vaccination and the risk of invasive cervical cancer. N Engl J Med. 2020;383:1340–8.CrossRefGoogle ScholarPubMed
HPV Vaccination Recommendations. In: Centers Dis. Control Prev. 2021. www.cdc.gov/vaccines/vpd/hpv/hcp/recommendations.html. Accessed April 8, 2022.Google Scholar
Meites, E., Kempe, A., Markowitz, L. E. Use of a 2-dose schedule for human pappilomavirus vaccination: Updated recommendations of the Advisory Committee on Immunization Practices. Morb Mortal Wkly Rep. 2016;65:1405–8.Google Scholar
Murphy, J., McKenna, M., Abdelazim, S., Battiwalla, M., Stratton, P. A practical guide to gynecologic and reproductive health in women undergoing hematopoietic stem cell transplant. Biol Blood Marrow Transplant. 2019;25:e331e343.CrossRefGoogle ScholarPubMed
Cherven, B., Klosky, J. L., Chen, Y., et al. Sexual behaviors and human papillomavirus vaccine non-initiation among young adult cancer survivors. J Cancer Surviv. 2021;15:942–50.CrossRefGoogle ScholarPubMed
Klosky, J., Russell, K., Canavera, K., et al. Risk factors for non-initiation of the human papillomavirus (HPV) vaccine among adolescent survivors of childhood cancer. Cancer Prev Res. 2013;6:1101–10.CrossRefGoogle ScholarPubMed
Wingo, P. A., Cardinez, C. J., Landis, S. H., et al. Long-term trends in cancer mortality in the United States, 1930–1998. Cancer. 2003;97:3133–275.CrossRefGoogle ScholarPubMed
Leyden, W. A., Manos, M. M., Geiger, A. M., et al. Cervical cancer in women with comprehensive health care access: Attributable factors in the screening process. J Natl Cancer Inst. 2005;97:675–83.CrossRefGoogle ScholarPubMed
Huh, W. K., Ault, K. A., Chelmow, D., et al. Use of primary high-risk human papillomavirus testing for cervical cancer screening: Interim clinical guidance. Gynecol Oncol. 2015;136:178–82.CrossRefGoogle ScholarPubMed
Monsonego, J., Cox, J. T., Behrens, C., et al. Prevalence of high-risk human papilloma virus genotypes and associated risk of cervical precancerous lesions in a large U.S. screening population: Data from the ATHENA trial. Gynecol Oncol. 2015;137:4754.CrossRefGoogle Scholar
Cuzick, J., Clavel, C., Petry, K. U., et al. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer. 2006;119:1095–101.CrossRefGoogle ScholarPubMed
Ogilvie, G. S., Van Niekerk, D., Krajden, M., et al. Effect of screening with primary cervical HPV testing vs cytology testing on high-grade cervical intraepithelial neoplasia at 48 months: The HPV FOCAL randomized clinical trial. JAMA – J Am Med Assoc. 2018;320:4352.CrossRefGoogle ScholarPubMed
Saslow, D., Solomon, D., Lawson, H., et al American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology Screening Guidelines for the Prevention and Early Detection of Cervical Cancer. CA Cancer J Clin. 2012;62:147–72.CrossRefGoogle ScholarPubMed
Curry, S. J., Krist, A. H., Owens, D. K., et al Screening for cervical cancer us preventive services task force recommendation statement. JAMA – J Am Med Assoc. 2018;320:674–86.Google ScholarPubMed
Fontham, E. T. H., Wolf, A. M. D., Church, T. R., et al Cervical cancer screening for individuals at average risk: 2020 guideline update from the American Cancer Society. CA Cancer J Clin. 2020;70:321–46.CrossRefGoogle ScholarPubMed
Perkins, R. B., Guido, R. S., Castle, P. E., et al. 2019 ASCCP risk-based management consensus guidelines for abnormal cervical cancer screening tests and cancer precursors. J Low Genit Tract Dis. 2020;24:102–31.Google ScholarPubMed
Moscicki, A. B., Flowers, L., Huchko, M. J., et al. Guidelines for cervical cancer screening in immunosuppressed women without HIV infection. J Low Genit Tract Dis. 2019;23:87101.CrossRefGoogle ScholarPubMed
Chang, H. A., Armenian, S. H., Dellinger, T. H. Secondary neoplasms of the female lower genital tract after hematopoietic cell transplantation. JNCCN J Natl Compr Cancer Netw. 2018;16:211–18.Google ScholarPubMed
Vegunta, S., Files, J. A., Wasson, M. N. Screening women at high risk for cervical cancer: Special groups of women who require more frequent screening. Mayo Clin Proc. 2017;92:1272–7.CrossRefGoogle ScholarPubMed
Hilal, Z., Tempfer, C. B., Burgard, L., Rehman, S., Rezniczek, G. A. How long is too long? Application of acetic acid during colposcopy: A prospective study. Am J Obstet Gynecol. 2020;223(101):e1–101.e8CrossRefGoogle Scholar
Massad, L. S., Einstein, M. H., Huh, W. K., et al. 2012 Updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. Obstet Gynecol. 2013;121:829–46.CrossRefGoogle ScholarPubMed
Martin-Hirsch, P. P. L., Paraskevaidis, E., Bryant, A., Dickinson, H. O. Surgery for cervical intraepithelial neoplasia. Cochrane Database Syst Rev. 2013. https://doi.org/10.1002/14651858.CD001318.pub3CrossRefGoogle Scholar

Save book to Kindle

To save this book to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×